Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Pr

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has received a consensus recommendation of “Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued a report on the stock in the last […]

Related Keywords

Nancyj Hutson , Stevenk Galson , , Insider Transactions At Biocryst Pharmaceuticals , Institutional Trading Of Biocryst Pharmaceuticals , Tower Research Capital , Biocryst Pharmaceuticals Company Profile , Biocryst Pharmaceuticals , Biocryst Pharmaceuticals Stock Down , Biocryst Pharmaceuticals Inc , Fifth Third Bancorp , Analyst Recommendations For Biocryst Pharmaceuticals , Securities Exchange Commission , Nasdaq , Third Bancorp , News Ratings For Biocryst Pharmaceuticals Daily , Needham Company , Get Free Report , Director Steven , Director Nancy , Exchange Commission , Eight Capital , Research Capital , Cryst Pharmaceuticals Stock Down , Cryst Pharmaceuticals , Get Free , Biocryst Pharmaceuticals Daily ,